奈达铂结合紫杉醇与培美曲塞对晚期肺腺癌患者肿瘤标志物水平及生存质量的影响

Effects of nedaplatin combined with paclitaxel and pemetrexed on tumor markers and quality of life in patients with advanced lung adenocarcinoma

目的探讨奈达铂结合紫杉醇与培美曲塞对晚期肺腺癌患者肿瘤标志物水平及生存质量的影响。方法选取本院2019年1月至12月收治的70例晚期肺腺癌患者,随机分为对照组与观察组,各35例。对照组采用奈达铂结合紫杉醇治疗,观察组采用奈达铂结合培美曲塞治疗。比较两组临床疗效、肿瘤标志物水平、生存质量及不良反应发生率。结果治疗后,与对照组相比,观察组总有效率、QOL评分较高,血清CYFRA21-1、CEA、CA125水平、不良反应发生率较低,差异有统计学意义(均P<0.05)。结论相较于奈达铂结合紫杉醇,奈达铂结合培美曲塞治疗晚期肺腺癌效果更优,可降低肿瘤标志物水平,提高患者生存质量,且不良反应少,安全性高。

Objective To investigate the effects of nedaplatin combined with paclitaxel and pemetrexed on tumor markers and quality of life in patients with advanced lung adenocarcinoma.Methods 70 patients with advanced lung adenocarcinoma admitted to our hospital from January to December,2019 were randomly divided into a control group and an observation group,with 35 cases in each group.The control group was treated with nedaplatin and paclitaxel,and the observation group with nedaplatin and pemetrexed.The clinical efficacies,tumor marker levels,quality of life,and incidences of adverse reactions were compared between the two groups.Results After the treatment,the total effective rate and QOL score were higher and the serum levels of CYFRA21-1,CEA,and CA125 and the incidence of adverse reactions were significantly lower in the observation group than in the control group(all P<0.05).Conclusion Nedaplatin combined with pemetrexed is more effective in the treatment of advanced lung adenocarcinoma than nedaplatin combined with paclitaxel,and can reduce the levels of tumor markers and improve the patients’quality of life,with fewer adverse reactions and high safety.